

AHA/ACOG PRESIDENTIAL ADVISORY

Promoting Risk Identification and Reduction of Cardiovascular Disease in Women Through Collaboration With Obstetricians and Gynecologists

A Presidential Advisory From the American Heart Association and the American College of Obstetricians and Gynecologists

In 2001, the Institute of Medicine (now known as the National Academy of Science) published a seminal monograph, *Exploring the Biological Contributions to Human Health: Does Sex Matter?*,¹ describing the importance of both sex and gender on human biology and physiology. Gender-specific medicine, which recognizes gender differences and similarities in cardiovascular disease recognition, prevention, and management, has exerted a powerful salutatory effect on women. Significant improvement in mortality and morbidity rates in women have been seen over the past 2 decades, in part as a result of initiatives such as the American Heart Association's (AHA's) Go Red For Women movement. Go Red For Women initially focused on raising awareness of heart disease as the No. 1 killer of women. This campaign expanded gender-focused research and the development of gender-based guidelines that led to a significant reduction in the rates of death among women.

Despite these advances, gender-based inequalities continue, with women being less likely to receive guideline-recommended diagnostic testing and therapies. Furthermore, despite the above-stated declines in mortality, more recently there has been an increase in mortality rates in women.² Despite significant efforts to raise awareness about heart disease, the most recent data show that only 45% of women identify heart disease as their leading cause of death and that fewer than half of primary care physicians consider cardiovascular disease to be a top concern in women, after breast health and weight.³

A majority of women consider their obstetrician/gynecologist (OB/GYN) to be their primary care physician, particularly women during their childbearing years, and we know that many of the life-span milestones for women impart unique effects on cardiovascular health, particularly pregnancy and menopause. Shaw et al⁴ use the term *healthcare team for women* to describe the importance of collaboration among clinicians who care for women in order to improve quality and equitable healthcare gaps in women. We now know that 90% of women have at least 1 risk factor for developing heart disease and that optimal prevention strategies (eg, the AHA's Life's Simple 7) begin decades before clinical heart disease is apparent. For these and many other reasons, a partnership with an OB/GYN to optimize early identification and modification of risk factors for heart disease and stroke can be a critical element in improving women's health.

CURRENT STATE OF CARE FOR WOMEN

Traditional Cardiovascular Risk Factors

Traditional atherosclerotic cardiovascular disease (ASCVD) risk factors, such as hypertension, diabetes mellitus, hypercholesterolemia, and obesity, affect both sexes, but some may affect women differently and are considered to be more

Haywood L. Brown, MD,
Co-Chair*

John J. Warner, MD,
FAHA, Co-Chair†

Eugenia Gianos, MD
Martha Gulati, MD, MS,
FAHA

Alexandria J. Hill, MD

Lisa M. Hollier, MD

Stacey E. Rosen, MD,
FAHA

Mary L. Rosser, MD, PhD

Nanette K. Wenger, MD,
FAHA

On behalf of the American
Heart Association and
the American College
of Obstetricians and
Gynecologists

*Haywood L. Brown, MD, is president of the American College of Obstetricians and Gynecologists.

†John J. Warner, MD, FAHA, is president of the American Heart Association.

Key Words: AHA Scientific Statements
■ cardiovascular diseases ■ prevention
■ risk factors ■ women's health

© 2018 by the American Heart Association, Inc., and the American College of Obstetricians and Gynecologists.

<http://circ.ahajournals.org>

potent. The population-adjusted risk of cardiovascular mortality is greater for women than men: 20.9% versus 14.9%.⁵ The impressive correlation of increased body mass index with elevated systolic blood pressure is noteworthy. After 65 years of age, women are more likely to be hypertensive than men, and the concern is that only 29% of elderly women have adequate blood pressure management, in contrast to 41% of men.² Furthermore, diabetes mellitus confers a greater cardiovascular risk for women than men: 19.1% versus 10.1%.^{5,6} Regardless of the presence of type 1 or type 2 diabetes mellitus, there is an increased risk for ASCVD in women to a greater degree than in men.⁷ Unfortunately, diabetic women are less likely than diabetic men to be treated for cardiovascular risk factors.

Hypercholesterolemia imparts the highest population-adjusted cardiovascular risk for women at 47%; benefits of statin therapy are similar for women and men.^{5,8} The new Pooled Cohort Risk Equations, which are gender-specific⁹ and should be used for cholesterol management with lifestyle guidelines,¹⁰ are applicable to both genders.

Given that 2 of 3 women in the United States are either obese or overweight, we must be cognizant of the adverse associations that increased weight has on cardiovascular health, including additive risk for hypertension, dyslipidemia, physical inactivity, and insulin resistance.^{5,11} Obese women also have a higher coronary artery disease risk at 64% compared with obese men (46%). We are also aware that psychosocial problems, particularly depression, preferentially disadvantage women.^{12,13} In the INTERHEART study (The Effect of Potentially Modifiable Risk Factors Associated With Myocardial Infarction), psychosocial factors were associated with cardiovascular mortality more for women (45.2%) than men (28.8%).⁵

Cardiovascular risk for women who smoke is 25% greater than for male smokers,¹⁴ and smoking is one of the strongest risk factors for ASCVD. In addition, cigarette use combined with oral contraceptives increases the risk of stroke,¹⁵ and smoking is more prevalent among younger women than younger men, with 16.7% of US women being smokers.

Physical inactivity is the most prevalent risk factor for women in that one fourth of US women report no regular physical activity and three fourths report less than the recommended amount.¹⁰ In the INTERHEART study, exercise provided a greater protective effect for women than for men.⁵ Specific data for women from the Nurses' Health Study identified a decrease in the development of diabetes mellitus in women who exercise regularly and, among diabetic women, a decrease in the risk of cardiovascular events with physical activity.^{16,17} Finally, women are

55% less likely than men to participate in cardiac rehabilitation.

Nontraditional Risk Factors Unique to or Predominant in Women

There are also certain ASCVD risk factors and conditions that are not necessarily sex specific but rather are female predominant.¹⁸ These include certain autoimmune disorders, including, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, and scleroderma.¹⁹ These disorders are highly prevalent among women who have an increased risk of coronary artery disease and other cardiovascular disease.^{20–22} Breast cancer predominantly affects women, and its treatments increase the risk of cardiovascular disease, with the increased risk in ASCVD becoming manifest just 7 years after breast cancer diagnosis.²³ These adverse outcomes warrant screening and intervention for cardiovascular risk factors in these populations.

Sex-Specific ASCVD Risk Factors

There are unique ASCVD risk factors for women, many related to pregnancy or hormonal influences. The impact of adverse pregnancy outcomes is emerging as an important predictor of future cardiovascular disease risk. Complications of pregnancy, including preeclampsia, gestational diabetes mellitus, gestational hypertension, preterm delivery, and low-for-estimated-gestational-age birth weight, indicate a subsequent increase in cardiovascular risk.^{20,24–28} Pregnancy is essentially a “stress test” for women, and these adverse pregnancy outcomes can be used to identify women who are at an increased risk for ASCVD, even in those for whom the conditions resolve after delivery. Preeclampsia and gestational hypertension impart a 3- to 6-fold increased risk of subsequent hypertension and a 2-fold risk for ischemic heart disease and stroke. Furthermore, these risk factors often do not translate to women as a predictor of future risk for ASCVD and are often not assessed when standard ASCVD risk assessment tools are used.²⁹ Unfortunately, these adverse pregnancy outcomes also may never be part of a patient's electronic health record, even if the delivery occurred in the same institution where the woman received primary care and risk assessment. Nonetheless, there is a highly accurate degree of recall of pregnancy-related events in women,³⁰ and a detailed pregnancy history should be included in the health record and referred to by those providing primary or disease-related health care to reproductive-age and postmenopausal women.

Other unique risk factors for women include polycystic ovarian syndrome,⁴ functional hypothalamic amen-

Table. Female Sex and Cardiovascular Disease Risk Factors

Female-Specific CVD Risk Factors	Female-Predominant CVD Risk Factors
Adverse pregnancy outcomes	Autoimmune inflammatory diseases
Pregnancy-related hypertension	Rheumatoid arthritis
Gestational hypertension	Systemic lupus erythematosus
Preeclampsia	Scleroderma
Eclampsia	
Gestational diabetes mellitus	
Preterm delivery	
Low birth weight for gestational age	
Polycystic ovarian syndrome	Breast cancer
Functional hypothalamic amenorrhea	
Reproductive hormones	
Oral contraceptives	
Hormone replacement	

CVD indicates cardiovascular disease.

Modified from Gulati.¹⁸ Copyright © 2017, American Heart Association, Inc.

orrhea,³¹ menopausal status, and hormone use, none of which are assessed in contemporary risk assessment tools (Table). These risk factors should be assessed in women to ensure that traditional ASCVD risk factors are controlled for and periodically reassessed.

Hormone Therapy

Most oral contraceptives do not impart an increase in cardiovascular risk for healthy women without traditional cardiovascular risk factors. However, oral contraceptive use by women who are cigarette smokers is associated with a 7-fold increase in cardiovascular risk, and hypertensive women are likely to have an elevation in blood pressure in association with oral contraceptive therapy. Stroke risk is increased by 1.4- to 2.0-fold, with its risk being more prominent among older women.^{32–34}

In a Canadian population,³⁵ women with successful fertility therapy had a decrease in many cardiovascular events, whereas women with unsuccessful fertility therapy were at increased cardiovascular risk. Therefore, the use of oral contraceptives and hormonal therapy for infertility should be included in the health record.

RECOMMENDATIONS FOR CARDIOVASCULAR PREVENTION

Many women see their OB/GYN as their sole physician, and this presents a unique opportunity to leverage this relationship to optimize risk reduction initiatives, reduce long-term healthcare costs, and provide comprehensive well-woman care. The American College of Obstetri-

cians and Gynecologists workforce found a decreasing number of office-based general internists and a significant reduction of family physicians performing deliveries and suggests that the role of the OB/GYN should increase as the coordinator of women's health care. Experts continue to emphasize the primary healthcare provider role for any young women at the entry point into the healthcare system.³⁶ Because OB/GYNs are primary care providers for many women, the well-woman visit is the foundation of practice. The annual visit provides a powerful opportunity to counsel patients about maintaining a healthy lifestyle and minimizing health risks.³⁷

An optimal well-woman cardiovascular prevention visit should include a thorough family history, screening for and targeted review of cardiovascular risk factors (including those unique to women), and lifestyle counseling to improve cardiovascular risk factors with the goal of preventing future cardiovascular events. The preferred approach is to begin early in a woman's life to maximize opportunities to prevent atherosclerosis, a slow, progressive disease that often begins in young adulthood or earlier. Recommendations for screening intervals to assess cardiovascular disease risk factors vary between societies, with some commonalities. The American College of Cardiology/AHA guidelines for the assessment of cardiovascular risk find it reasonable to screen adults free of cardiovascular disease for risk factors such as smoking, hypertension, diabetes mellitus, total cholesterol, and high-density lipoprotein cholesterol every 4 to 6 years between the ages of 20 and 79 years to calculate their 10-year cardiovascular risk. Either 30-year or lifetime cardiovascular disease risk estimation can be used in adults 20 to 59 years of age with a 10-year risk of cardiovascular disease <7.5%.⁹ To efficiently screen a woman for cardiovascular disease risk, both the traditional and nontraditional risk factors described above and highlighted in the Table should be considered. Nontraditional risk factors may affect the aggressiveness of the preventive treatment and may guide the initiation of preventive medications such as statins and antiplatelet drugs.

All well-woman visits, including the postpartum follow-up visit, should be considered an opportunity to focus on lifestyle choices that optimize cardiac health, including weight management, smoking cessation, physical activity assessment, nutritional counseling, and stress reduction. This is especially important for those with pregnancy complications that suggest an increased risk for premature cardiovascular events.

Diabetes Mellitus and Abnormal Glucometabolic State

The US Preventive Services Task Force suggests screening for abnormal blood glucose in adults 40 to 70 years

of age who are overweight or obese. It is also reasonable to screen those with a family history of diabetes mellitus or established cardiovascular disease according to American Diabetes Association recommendations. Patients with diabetes mellitus (defined as hemoglobin A_{1c} >6.4%) should be treated to achieve hemoglobin A_{1c} <7.0%. Prediabetes should be defined as hemoglobin A_{1c} of 5.7% to 6.4%. All patients with diabetes mellitus, prediabetes, or metabolic syndrome should receive lifestyle counseling, which has been shown to have even better outcomes than medical therapy.³⁸ Women with gestational diabetes mellitus should be screened for diabetes mellitus postpartum and receive counseling on increased risk and periodic screening based on current guidelines.³⁹ Metabolic syndrome (defined in women as 3 of the following 5 components: blood pressure >130 mm Hg systolic or 85 mm Hg diastolic, triglycerides >150 mg/dL, high-density lipoprotein <50 mg/dL, fasting glucose >100 mg/dL, waist circumference >35 in)⁴⁰ has also been recognized for putting women at increased risk for cardiovascular events, with each component being highly susceptible to lifestyle changes.⁴¹

Hyperlipidemia

The AHA recommends that all adults ≥20 years of age have their cholesterol and other traditional risk factors checked every 4 to 6 years. In addition, if the family history suggests a genetic lipid disorder such as markedly elevated lipids with a family history of premature cardiovascular disease, it is imperative to check lipids on the initial visit regardless of age because cardiovascular event rates are far greater in those with genetic lipid disorders.^{42,43}

Women with elevated lipids should receive counseling to lower their intake of saturated fats and to increase dietary fiber through a DASH (Dietary Approaches to Stop Hypertension), Mediterranean, or plant-based whole-food diet.^{44,45} If diet alone is not adequate to achieve optimal lipid levels, statins are the first-line agent for cardiovascular event reduction. However, women of child-bearing age need to be specifically counseled to not become pregnant while taking a statin. The data to date for statins in pregnancy are mixed, but current guidelines still recommend against their use.^{29,46} Although elevated triglycerides portend increased cardiovascular risk, particularly in women, treatment with medical therapy is suggested when triglycerides are >500 mg/dL because this carries an elevated risk of pancreatitis. In addition to appropriate dietary counseling and supplementation with omega-3 fatty acids, pregnant patients with familial hypertriglyceridemia, particularly with a history of pancreatitis, may benefit from the use of fenofibrates when triglyceride levels are >1000 mg/dL, particularly in the face of other comorbidities such as hypertension and diabetes mellitus.⁴⁷

Hypertension

The AHA recommends that blood pressure should be screened during regular healthcare visits at least once every 2 years for anyone ≥20 years of age.⁴⁸ The US Preventive Services Task Force recommends that adults ≥40 years and individuals at increased risk for high blood pressure should be screened annually.⁴⁹ Blood pressures should be checked with proper technique to ensure that patients are treated on the basis of accurate measurements.^{50–52} Home blood pressure monitors or ambulatory blood pressure monitors may also be needed to confirm true hypertension. New American College of Cardiology/AHA 2017 guidelines define an elevated blood pressure as a systolic blood pressure of 120 to 129 mm Hg and a diastolic blood pressure <80 mm Hg, stage 1 hypertension as a systolic blood pressure of 130 to 139 mm Hg or a diastolic blood pressure of 80 to 89 mm Hg, and stage 2 hypertension as a systolic blood pressure of at least 140 mm Hg or a diastolic blood pressure of at least 90 mm Hg.⁵² Lifestyle guidance should be given to all patients with elevated blood pressures. Causes of hypertension to assess include obesity, excess sodium intake, low-fiber diets, physical inactivity, excess alcohol intake, and sleep apnea.

Women without cardiovascular disease or elevated risk for cardiovascular disease should be treated with medical therapy if their blood pressure measurements are >140/90 mm Hg. However, if they have established cardiovascular disease or an elevated cardiovascular risk such as a 10-year risk >10%, treatment should begin at blood pressures >130/80 mm Hg.⁵²

Contraceptive agents such as low-dose estrogen (eg, 20–30 µg of ethinyl estradiol), progestin only, intrauterine devices (copper or progestin releasing), barrier methods, or abstinence are recommended in women with established hypertension; avoidance of typical combined oral contraceptive pills in women with uncontrolled hypertension is suggested.⁵²

Optimal Weight and Weight Loss

Checking a patient's weight at every visit and discussing the patient's progress can prove effective to achieve behavioral change. Achieving an ideal weight can have benefits on all cardiovascular risk factors⁵³ and reproductive outcomes.⁵⁴ In many cases, referral to a registered dietician or a weight loss program can prove successful for more specific guidance and patient accountability. The interconception and postpartum visits provide an excellent opportunity to counsel women on achieving a healthier weight. Excessive weight gain during pregnancy is associated with significant retention of weight after pregnancy and into adult life.

Diet and Nutritional Concerns

To date, the DASH diet and the Mediterranean diet have the highest level of evidence for cardiovascular protection, with more plant-based options conveying an even greater benefit.^{55,56} Optimal diets have been shown to reduce cardiovascular and cancer risks and can be essential for reproductive health.⁵⁷ Assessing a patient's diet during an office visit may best be done by simple food frequency questionnaires (Mediterranean Diet Score, Rate Your Plate) to potentially guide a patient to areas for improvement. In the absence of a specific nutritional deficiency, there is no role for supplementation with vitamins, folic acid, or vitamin E for cardiovascular risk reduction.⁵⁸ Obtaining nutrients from a well-balanced diet is key, with dietary patterns for reduction of cardiovascular disease being more effective than a focus on individual nutrients.^{58,59}

Physical Activity

The American College of Cardiology/AHA 2013 lifestyle guidelines suggest that women engage in 150 min/wk of moderate-intensity physical activity, 75 min/wk of vigorous-intensity aerobic physical activity, or an equivalent combination of moderate- and vigorous-intensity aerobic physical activity. This can be performed in episodes of at least 10 minutes, preferably spread throughout the week.¹⁰ In addition, the AHA advocates for attaining 10 000 steps daily (\approx 5 miles) for the maintenance of heart health. Encouraging women to get this activity in divided doses, based on their specific daily activities, can make this goal more achievable. Pregnant women may experience benefits from exercise in pregnancy, including a reduction in preeclampsia and gestational diabetes mellitus.⁶⁰ The American College of Obstetricians and Gynecologists supports exercise in pregnancy: 20 to 30 minutes of moderate-intensity exercise most or all days in a week (when not contraindicated), which can include aerobic and strength conditioning.⁶⁰

Smoking Cessation

The recommended practice for smoking cessation assessment is the use of the 5 As: (1) ask about smoking; (2) advise the patient to quit through clear, personalized messages; (3) assess willingness to quit; (4) assist in quitting; and (5) arrange follow-up and support. In-person behavioral counseling sessions, even when <10 minutes, effectively increase the proportion of adults who successfully quit smoking and remain abstinent for 1 year. Although less effective, even interventions <3 minutes in duration increase cessation rates in some studies. Recommendations for smoking cessation include behavioral interventions and US Food and Drug Administration–approved pharmacotherapy. Combining behavioral and pharmacotherapy interventions may increase cessation rates from \approx 8% to 14%⁴⁹ compared

with usual care or minimal behavioral interventions such as self-help materials or brief advice on quitting.^{61,62}

Mental Health and Stress Reduction

Mental health and stress reduction are imperative at all stages of life, but perhaps more so in stages of a woman's life that are influenced by hormonal and environmental factors, particularly postpartum and menopause.⁶³ After both myocardial infarction and stroke, women tend to have higher incidences of depression (odds ratio, 1.27–3.15; hazard ratio, 3.52).^{21,64,65} Mental health can affect cardiovascular health and attainment of optimal risk factors. In the healthcare realm overall, mental health and reduction of stress are often overlooked, even though they can greatly affect patient outcomes. There are data to suggest that programs for mindfulness and meditation improve a woman's well-being.

My Life Check and Life's Simple 7

The AHA constructed the 2020 Impact Goal to improve the cardiovascular health of all Americans with 7 health metrics defining ideal cardiovascular health.⁶⁶ Based on 4 behavioral factors (smoking, physical activity, diet, and weight) and 3 health factors (total cholesterol, blood pressure, and metabolic control), scores are divided into ideal, intermediate, or poor levels of attainment. Providing feedback to patients about their risk level and tracking their progress can be a simple way to improve behaviors.

LIFE SPAN–SPECIFIC RECOMMENDATIONS

The above recommendations for risk factor recognition and treatment are universal to women of all ages. At specific stages of a woman's life, however, healthcare providers should be more attuned to specific factors. Numerous studies have demonstrated that OB/GYNs are a major gateway into women's care and can positively influence a woman's lifetime health.

Menarche to Premenopause

Development of heart-healthy behaviors can have an even greater impact on cardiovascular disease reduction and reproductive health at this age. A detailed family history is critical during this period for estimating the patient's cardiovascular risks. Careful assessment and counseling should be done before the initiation of any oral contraceptives during this time period.

Pregnancy

Pregnancy has been referred to as the physiological stress test that reveals underlying disease processes.

Risk factor assessment has shown that 30% to 40% of pregnant women have 1 risk factor that can lead to long-term health problems and that 20% to 30% carry a predictor of cardiovascular disease risk. Because only specific drugs have been tested in pregnancy, recommendations for medical treatment of cardiovascular risk factors should be limited to those deemed safe in pregnancy on the basis of established guidelines.⁶⁰ Because a number of medications for lipid lowering and smoking cessation are not deemed safe during pregnancy, behavioral counseling can play a critical role during this period, as can more aggressive medical therapy during the times when a woman is not trying to conceive. Pregnant women should be counseled on following the Institute of Medicine guidelines for weight gain during pregnancy based on prepregnancy body mass index and make an attempt to achieve a healthier weight between pregnancies if they are overweight or obese.

Premenopause and Postmenopause

Recognizing both traditional and nontraditional cardiovascular disease risk factors is imperative for optimal medical therapy and lifestyle guidance. Decisions about the use of hormone replacement therapy should also be guided by a thorough risk assessment.

CONCLUSIONS AND RECOMMENDATIONS

Because cardiovascular disease continues to be the leading cause of death in women, we are obligated to seize the opportunity with an urgent call to action. Clinicians who provide care to women must take an active role in chronic disease prevention. Coordinated health-care delivery among OB/GYNs and cardiologists would allow a better assessment of patient needs and improve outcomes by minimizing cardiovascular morbidity and mortality. To facilitate these improvements in care, we propose a set of principles to guide the identification and prevention of cardiovascular disease in women.

1. Healthy lifestyles and behaviors should be a point of emphasis in the care of all women. The poor Western diet and lack of exercise are the root causes of poor outcomes such as cardiovascular disease and diabetes mellitus, leading to excessive healthcare costs. Multidisciplinary and innovative strategies should be developed to engage and empower women to change their lifestyles. Healthy behaviors should be discussed at each visit.
2. Screening for cardiovascular disease and cardiovascular risk factors in women should be enhanced. Eliciting a full patient history will reveal critical clues about patient risk factors and may trigger appropriate referrals. Preexamination questionnaires can

include surveys addressing diet, physical activity, depression screening, and lifestyle choices, as well as a detailed family and social history. Templates can be created for visits that include both traditional and nontraditional cardiovascular disease risk factors to ensure that the clinician has addressed all key areas such as genetic risk factors, smoking cessation, and mental health. Regular screening and risk review sends a consistent message to patients of the importance of healthful lifestyle adherence; a comprehensive and standardized approach to screening and risk identification is key.

3. Providers and healthcare systems should leverage technology to improve the cardiovascular health of women. Use of electronic health records and connecting medical data silos are crucial to providing integrated patient care. Software algorithms can trigger patient education and referrals by analyzing data contained in enhanced and comprehensive screenings. Consumer technology firms are developing devices and software to allow consumers to monitor and enhance their health. OB/GYNs and cardiologists should take an active role to ensure that the medical history collected is comprehensive, and key insights should trigger the correct recommendations and referrals to the appropriate physicians. These new consumer medical technologies should be leveraged to institute prevention and intervention strategies for behavioral change and extended to social media networks to educate, empower, and motivate women. Consumer devices, apps, and social media networks have the potential to reach most populations and to assist in reducing healthcare disparities.
4. OB/GYNs and cardiology providers can improve the cardiovascular health of women through enhanced collaboration. There is a significant opportunity to bridge the disciplines of cardiology and obstetrics and gynecology, including standardized protocols and enhanced cardiac screening. Shared information can be used to assess risk, initiate interventions, and facilitate significant lifestyle changes. Care can be coordinated to minimize cardiovascular morbidity and mortality and to improve outcomes. By providing a platform for comprehensive well-woman care, primary prevention, and early intervention, providers of women's health can provide patient education, empowerment, and motivation.

Educational Resources

Primary care clinicians may find the following resources useful in talking with adults and pregnant women about several health issues affecting women:

- AHA Life's Simple 7 website^{67,68}
- AHA Go Red For Women website⁶⁹

- Mediterranean diet—Go Red For Women⁷⁰
- How to reduce added sugar in diet—Go Red For Women⁷¹
- Pregnancy and heart disease—Go Red For Women⁷²
- AHA high blood pressure and women⁷³
- Gestational diabetes mellitus—Go Red For Women⁷⁴
- Committee on Practice Bulletins—Obstetrics: Practice Bulletin No. 180: Gestational Diabetes Mellitus³⁹
- AHA prevention and treatment of high cholesterol⁷⁵
- Smoking cessation: Centers for Disease Control and Prevention fact sheets on quitting smoking⁷⁶ and the US Department of Health and Human Services' BeTobaccoFree,⁷⁷ SmokeFree Women,⁷⁸ and Public Health Service 2008 clinical practice guidelines⁷⁹
- American College of Obstetricians and Gynecologists Patient Page⁸⁰

ARTICLE INFORMATION

The American Heart Association and the American College of Obstetricians and Gynecologists make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all

members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This advisory was approved by the American Heart Association Science Advisory and Coordinating Committee on May 1, 2018, and the American Heart Association Executive Committee on May 7, 2018. A copy of the document is available at <http://professional.heart.org/statements> by using either "Search for Guidelines & Statements" or the "Browse by Topic" area. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

The American Heart Association requests that this document be cited as follows: Brown HL, Warner JJ, Gianos E, Gulati M, Hill AJ, Hollier LM, Rosen SE, Rosser ML, Wenger NK; on behalf of the American Heart Association and the American College of Obstetricians and Gynecologists. Promoting risk identification and reduction of cardiovascular disease in women through collaboration with obstetricians and gynecologists: a presidential advisory from the American Heart Association and the American College of Obstetricians and Gynecologists. *Circulation*. 2018;137:e843–e852. DOI: 10.1161/CIR.0000000000000582.

The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <http://professional.heart.org/statements>. Select the "Guidelines & Statements" drop-down menu, then click "Publication Development."

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp. A link to the "Copyright Permissions Request Form" appears on the right side of the page.

Disclosures

Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Haywood L. Brown	Duke University	None	None	None	None	None	None	None
John J. Warner	UT Southwestern Medical Center	None	None	None	None	None	None	None
Eugenia Gianos	New York University Langone Health	None	None	None	None	None	Regeneron*	None
Martha Gulati	University of Arizona	None	None	None	None	None	None	None
Alexandria J. Hill	High Risk Pregnancy Center	None	None	None	None	None	None	None
Lisa M. Hollier	Texas Children's Hospital	None	None	None	None	None	None	None
Stacey E. Rosen	Northwell Health	None	None	None	None	None	None	None
Mary L. Rosser	New York–Presbyterian/Columbia University Medical Center	None	None	None	None	None	None	None
Nanette K. Wenger	Emory University School of Medicine	Gilead Sciences*; NHLBI*; Pfizer*; Society for Women's Health Research*	None	None	None	None	Amgen*; AstraZeneca*; Gilead Sciences*; Janssen Pharmaceutical*; Merck*	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Modest.

REFERENCES

- Institute of Medicine. *Exploring the Biological Contributions to Human Health: Does Sex Matter?* Washington, DC: The National Academies Press; 2001.
- Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CV, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2018 update: a report from the American Heart Association [published correction appears in *Circulation*. 2018;137:e493]. *Circulation*. 2018;137:e67–e492. doi: 10.1161/CIR.0000000000000558.
- Bairey Merz CN, Andersen H, Sprague E, Burns A, Keida M, Walsh MN, Greenberger P, Campbell S, Pollin I, McCullough C, Brown N, Jenkins M, Redberg R, Johnson P, Robinson B. Knowledge, attitudes, and beliefs regarding cardiovascular disease in women: the Women's Heart Alliance. *J Am Coll Cardiol*. 2017;70:123–132. doi: 10.1016/j.jacc.2017.05.024.
- Shaw LJ, Pepine CJ, Xie J, Mehta PK, Morris AA, Dickert NW, Ferdinand KC, Gulati M, Reynolds H, Hayes SN, Itchhaporia D, Mieres JH, Ofili E, Wenger NK, Bairey Merz CN. Quality and equitable health care gaps for women: attributions to sex differences in cardiovascular medicine. *J Am Coll Cardiol*. 2017;70:373–388. doi: 10.1016/j.jacc.2017.05.051.
- Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004;364:937–952. doi: 10.1016/S0140-6736(04)17018-9.
- Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. *Diabetologia*. 2014;57:1542–1551. doi: 10.1007/s00125-014-3260-6.
- Huxley RR, Peters SA, Mishra GD, Woodward M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol*. 2015;3:198–206. doi: 10.1016/S2213-8587(14)70248-7.
- Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. *J Am Coll Cardiol*. 2012;59:572–582. doi: 10.1016/j.jacc.2011.09.067.
- Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in *Circulation*. 2014;129(suppl 2):S74–S75]. *Circulation*. 2014;129(suppl 2):S49–S73. doi: 10.1161/01.cir.0000437741.48606.98.
- Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee I-M, Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC Jr, Svetkey LP, Wadden TA, Yanovski SZ. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published corrections appear in *Circulation*. 2014;129:S100–S101 and *Circulation*. 2015;131:e326]. *Circulation*. 2014;129(suppl 2):S76–S99. doi: 10.1161/01.cir.0000437740.48606.d1.
- Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society [published correction appears in *Circulation*. 2014;129(suppl 2):S139–S140]. *Circulation*. 2014;129(suppl 2):S102–S138. doi: 10.1161/01.cir.0000437739.71477.ee.
- Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Deering LV, Frasure-Smith N, Freedland KE, Jaffe AS, Leifheit-Limson EC, Sheps DS, Vaccarino V, Wulsin L; on behalf of the American Heart Association Statistics Committee of the Council on Epidemiology and Prevention and the Council on Cardiovascular and Stroke Nursing. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. *Circulation*. 2014;129:1350–1369. doi: 10.1161/CIR.0000000000000019.
- Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, Blackett KN, Sitthi-amorn C, Sato H, Yusuf S; INTERHEART Investigators. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004;364:953–962. doi: 10.1016/S0140-6736(04)17019-0.
- Hackshaw A, Morris JK, Boniface S, Tang JL, Milenković D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. *BMJ*. 2018;360:j5855.
- Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, Howard VJ, Lichtman JH, Lisabeth LD, Piña IL, Reeves MJ, Rexrode KM, Saposnik G, Singh V, Towfighi A, Vaccarino V, Walters MR; on behalf of the American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council for High Blood Pressure Research. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2014;45:1545–1588. doi: 10.1161/01.str.0000442009.06663.48.
- Hu FB, Stampfer MJ, Solomon C, Liu S, Colditz GA, Speizer FE, Willett WC, Manson JE. Physical activity and risk for cardiovascular events in diabetic women. *Ann Intern Med*. 2001;134:96–105.
- Manson JE, Rimm EB, Stampfer MJ, Colditz GA, Willett WC, Krolewski AS, Rosner B, Hennekens CH, Speizer FE. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. *Lancet*. 1991;338:774–778.
- Gulati M. Improving the cardiovascular health of women in the nation: moving beyond the bikini boundaries. *Circulation*. 2017;135:495–498. doi: 10.1161/CIRCULATIONAHA.116.025303.
- Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. *Eur Heart J*. 2015;36:482–489c. doi: 10.1093/eurheartj/ehu403.
- Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Piña IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D'Armiento J, Kris-Etherton PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CK, Jackson EA, Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier NA, Ofili E, Oparil S, Ouyang P, Pinn VW, Sherif K, Smith SC Jr, Sopko G, Chandra-Strobo N, Urbina EM, Vaccarino V, Wenger NK. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association [published corrections appear in *Circulation*. 2011;123:e624 and *Circulation*. 2011;124:e427]. *Circulation*. 2011;123:1243–1262. doi: 10.1161/CIR.0b013e31820faaf8.
- Zhang WN, Pan YH, Wang XY, Zhao Y. A prospective study of the incidence and correlated factors of post-stroke depression in China. *PLoS One*. 2013;8:e78981. doi: 10.1371/journal.pone.0078981.
- Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. *Am J Med*. 2008;121(suppl 1):S3–S8. doi: 10.1016/j.amjmed.2008.06.010.
- Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. *Epidemiology*. 2016;27:6–13. doi: 10.1097/EDE.0000000000000394.
- Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V. Pre-eclampsia and future cardiovascular risk among women: a review. *J Am Coll Cardiol*. 2014;63:1815–1822. doi: 10.1016/j.jacc.2014.02.529.
- Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ*. 2007;335:974. doi: 10.1136/bmj.39335.385301.BE.
- Fraser A, Nelson SM, Macdonald-Wallis C, Cherry L, Butler E, Sattar N, Lawlor DA. Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children. *Circulation*. 2012;125:1367–1380. doi: 10.1161/CIRCULATIONAHA.111.044784.
- Wenger NK. Recognizing pregnancy-associated cardiovascular risk factors. *Am J Cardiol*. 2014;113:406–409. doi: 10.1016/j.amjcard.2013.08.054.
- Wu P, Gulati M, Kwok CS, Wong CW, Narain A, O'Brien S, Chew-Graham CA, Verma G, Kadam UT, Mamas MA. Preterm delivery and future risk of maternal cardiovascular disease: a systematic review and meta-analysis. *J Am Heart Assoc*. 2018;7:e007809. doi: 10.1161/JAHA.117.007809.

29. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published corrections appear in *Circulation*. 2014;129:S46–S48 and *Circulation*. 2015;132:e396]. *Circulation*. 2014;129(suppl 2):S1–S45. doi: 10.1161/01.cir.0000437738.63853.7a.
30. Carter EB, Stuart JJ, Farland LV, Rich-Edwards JW, Zera CA, McElrath TF, Seely EW. Pregnancy complications as markers for subsequent maternal cardiovascular disease: validation of a maternal recall questionnaire. *J Womens Health (Larchmt)*. 2015;24:702–712. doi: 10.1089/jwh.2014.4953.
31. Bairey Merz CN, Johnson BD, Sharaf BL, Bittner V, Berga SL, Braunstein GD, Hodgson TK, Matthews KA, Pepine CJ, Reis SE, Reichel N, Rogers WJ, Pohost GM, Kelsey SF, Sopko G; WISE Study Group. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. *J Am Coll Cardiol*. 2003;41:413–419.
32. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study: WHO collaborative study of cardiovascular disease and steroid hormone contraception. *Lancet*. 1996;348:498–505.
33. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. *J Am Coll Cardiol*. 2009;53:221–231. doi: 10.1016/j.jacc.2008.09.042.
34. Bushnell C, McCullough L. Stroke prevention in women: synopsis of the 2014 American Heart Association/American Stroke Association guideline. *Ann Intern Med*. 2014;160:853–857. doi: 10.7326/M14-0762.
35. Udell JA, Lu H, Redelmeier DA. Long-term cardiovascular risk in women prescribed fertility therapy. *J Am Coll Cardiol*. 2013;62:1704–1712. doi: 10.1016/j.jacc.2013.05.085.
36. Rayburn WF. The obstetrician-gynecologist workforce in the United States: facts, figures, and implications. 2017. <https://www.acog.org/clinical-guidance-and-publications/the-ob-gyn-workforce/the-obstetrician-gynecologist-workforce-in-the-united-states>. Accessed May 2, 2018.
37. Committee Opinion No. 534: well-woman visit. *Obstet Gynecol*. 2012;120:421–424.
38. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346:393–403. doi: 10.1056/NEJMoa012512.
39. Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 180: gestational diabetes mellitus. *Obstet Gynecol*. 2017;130:e17–e37. doi: 10.1097/AOG.0000000000002159.
40. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement [published corrections appear in *Circulation*. 2005;112:e297 and *Circulation*. 2005;112:e298]. *Circulation*. 2005;112:2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404.
41. Bassi N, Karagodin I, Wang S, Vassallo P, Priyanath A, Massaro E, Stone NJ. Lifestyle modification for metabolic syndrome: a systematic review. *Am J Med*. 2014;127:1242.e1–1242.10. doi: 10.1016/j.amjmed.2014.06.035.
42. Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV, Underberg JA; NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia, part 2. *J Clin Lipidol*. 2015;9(suppl):S1–S122.e1. doi: 10.1016/j.jacl.2015.09.002.
43. Perak AM, Ning H, de Ferranti SD, Gooding HC, Wilkins JT, Lloyd-Jones DM. Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype. *Circulation*. 2016;134:9–19. doi: 10.1161/CIRCULATIONAHA.116.022335.
44. Holl ander PL, Ross AB, Kristensen M. Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. *Am J Clin Nutr*. 2015;102:556–572. doi: 10.3945/ajcn.115.109165.
45. Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller ER 3rd, Lin PH, Karanja NM, Most-Windhauser MM, Moore TJ, Swain JF, Bales CW, Proschan MA; DASH Research Group. Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. *Am J Clin Nutr*. 2001;74:80–89. doi: 10.1093/ajcn/74.1.80.
46. Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: a systematic review. *J Clin Lipidol*. 2016;10:1081–1090. doi: 10.1016/j.jacl.2016.07.002.
47. Hill AJ, Pacheco LD, Saade G, Hankins GD. Familial hypertriglyceridemia in pregnancy. *Int J Gynaecol Obstet*. 2014;125:80–81. doi: 10.1016/j.ijgo.2013.11.004.
48. American Heart Association. Heart-health screenings. http://www.heart.org/HEARTORG/Conditions/Heart-Health-Screenings_UCM_428687_Article.jsp#.WupOa9KWYUk. Accessed May 2, 2018.
49. US Preventive Services Task Force. Final recommendation statement: high blood pressure in adults: screening. September 2017. <https://www.uspreventiveservicestaskforce.org/page/document/recommendation-statementfinal/high-blood-pressure-in-adults-screening>. Accessed February 20, 2018.
50. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. *N Engl J Med*. 1997;336:1117–1124. doi: 10.1056/NEJM199704173361601.
51. Estruch R, Ros E, Salas-Salvad  J, Covas MI, Corella D, Ar s F, G mez-Gracia E, Ruiz-Guti rrez V, Fiol M, Lapetra J, Lamuela-Raventos JM, Serra-Majem L, Pint  X, Basora J, Mu oz MA, Sorl  JV, Mart nez JA, Mart nez-Gonz lez MA; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med*. 2013;368:1279–1290. doi: 10.1056/NEJMoa1200303.
52. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Oviagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71:e13–e115. DOI: 10.1161/HYP.0000000000000065.
53. Caleyachetty R, Thomas GN, Toulis KA, Mohammed N, Gokhale KM, Balachandran K, Nirantharakumar K, Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. *J Am Coll Cardiol*. 2017;70:1429–1437. doi: 10.1016/j.jacc.2017.07.763.
54. Marsh CA, Hecker E. Maternal obesity and adverse reproductive outcomes: reducing the risk. *Obstet Gynecol Surv*. 2014;69:622–628. doi: 10.1097/OGX.0000000000000115.
55. Fung TT, Chiuve SE, McCullough ML, Rexrode KM, Logroscino G, Hu FB. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. *Arch Intern Med*. 2008;168:713–720. doi: 10.1001/archinte.168.7.713.
56. Mart nez-Gonz lez MA, Sanchez-Tainta A, Corella D, Salas-Salvad  J, Ros E, Aros F, Gomez-Gracia E, Fiol M, Lamuela-Raventos RM, Schroder H, Lapetra J, Serra-Majem L, Pinto X, Ruiz-Guti rrez V, Estruch R. A provegetarian food pattern and reduction in total mortality in the Prevencion Con Dieta Mediterranea (PREDIMED) study. *Am J Clin Nutr*. 2014;100(suppl 1):320S–328S.
57. Karayiannis D, Kontogianni MD, Mendorou C, Mastrominas M, Yianakouris N. Adherence to the Mediterranean diet and IVF success rate among non-obese women attempting fertility [published online ahead of print January 30, 2018]. *Hum Reprod*. doi: 10.1093/humrep/dey003. <https://academic.oup.com/humrep/article-abstract/33/3/494/4828066?re-directedFrom=fulltext>.
58. Freeman AM, Morris PB, Barnard N, Esselstyn CB, Ros E, Agatston A, Devries S, O’Keefe J, Miller M, Ornish D, Williams K, Kris-Etherton P. Trending cardiovascular nutrition controversies. *J Am Coll Cardiol*. 2017;69:1172–1187. doi: 10.1016/j.jacc.2016.10.086.
59. Bowen KJ, Sullivan VK, Kris-Etherton PM, Petersen KS. Nutrition and cardiovascular disease: an update. *Curr Atheroscler Rep*. 2018;20:8. doi: 10.1007/s11883-018-0704-3.
60. ACOG Committee Opinion No. 650: physical activity and exercise during pregnancy and the postpartum period. *Obstet Gynecol*. 2015;126:e135–e142.
61. Siu AL; US Preventive Services Task Force. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: US Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2015;163:622–634. doi: 10.7326/M15-2023.

62. US Preventive Services Task Force. US Preventive Services Task Force final recommendation statement: tobacco smoking cessation in adults, including pregnant women: behavioral and pharmacotherapy interventions. <https://www.uspreventiveservicestaskforce.org/page/document/recommendationstatementfinal/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions1>. Accessed February 20, 2018.
63. Bhat A, Reed SD, Unützer J. The obstetrician-gynecologist's role in detecting, preventing, and treating depression. *Obstet Gynecol*. 2017;129:157–163. doi: 10.1097/AOG.0000000000001809.
64. Shi Y, Xiang Y, Yang Y, Zhang N, Wang S, Ungvari GS, Chiu HF, Tang WK, Wang Y, Zhao X, Wang Y, Wang C. Depression after minor stroke: prevalence and predictors. *J Psychosom Res*. 2015;79:143–147. doi: 10.1016/j.jpsychores.2015.03.012.
65. Tsai CS, Wu CL, Hung TH, Chou SY, Su JA. Incidence and risk factors of poststroke depression in patients with acute ischemic stroke: a 1-year prospective study in Taiwan. *Biomed J*. 2016;39:195–200. doi: 10.1016/j.bj.2015.10.004.
66. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenland K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD; on behalf of the American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. *Circulation*. 2010;121:586–613. doi: 10.1161/CIRCULATIONAHA.109.192703.
67. American Heart Association. Life's Simple 7. <http://heartinsight.heart.org/Lifes-Simple-7/>. Accessed May 2, 2018.
68. American Heart Association. My Life Check—Life's Simple 7. http://www.heart.org/HEARTORG/Conditions/My-Life-Check—Lifes-Simple-7_UCM_471453_Article.jsp#.Ws-hXHkovIU. Accessed May 2, 2018.
69. American Heart Association. Go Red For Women. http://www.heart.org/HEARTORG/Causes/Causes_UCM_001128_SubHomePage.jsp. Accessed May 2, 2018.
70. American Heart Association. Mediterranean diet and heart health. https://www.goredforwomen.org/about-heart-disease/heart_disease_research-subcategory/mediterranean-diet-and-heart-health/. Accessed May 2, 2018.
71. American Heart Association. How to reduce added sugar in your diet. <https://www.goredforwomen.org/live-healthy/first-steps-to-prevent-heart-disease-and-be-heart-healthy/reduce-added-sugar-diet/>. Accessed May 2, 2018.
72. American Heart Association. Pregnancy and heart disease. https://www.goredforwomen.org/know-your-risk/birth_control_pregnancy_heart_disease/pregnancy-and-heart-disease/. Accessed May 2, 2018.
73. American Heart Association. High blood pressure and women. http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/UnderstandYourRiskforHighBloodPressure/High-Blood-Pressure-and-Women_UCM_301867_Article.jsp#.Ws-hsnKovIU. Accessed May 2, 2018.
74. American Heart Association. Gestational diabetes may raise heart risk. https://www.goredforwomen.org/about-heart-disease/heart_disease_research-subcategory/gestational-diabetes-heart-disease-risk/. Accessed May 2, 2018.
75. American Heart Association. Prevention and treatment of high cholesterol (hyperlipidemia). http://www.heart.org/HEARTORG/Conditions/Cholesterol/PreventionandTreatmentofHighCholesterol/Prevention-and-Treatment-of-High-Cholesterol_UCM_001215_Article.jsp#.Ws-nUnKovIU. Accessed May 2, 2018.
76. Centers for Disease Control and Prevention. Quitting smoking. http://www.cdc.gov/tobacco/data_statistics/fact_sheets/cessation/quitting/index.htm. Accessed May 2, 2018.
77. US Department of Health and Human Services. Quit now. <http://betobaccofree.hhs.gov/quit-now/index.html#professionals>. Accessed May 2, 2018.
78. US Department of Health and Human Services. Pregnancy & motherhood. <http://women.smokefree.gov/pregnancy-motherhood.aspx>. Accessed May 2, 2018.
79. US Department of Health and Human Services. Treating tobacco use and dependence: 2008 update. <https://bphc.hrsa.gov/buckets/treatingtobacco.pdf>. Accessed May 2, 2018.
80. American College of Obstetricians and Gynecologists. ACOG Patient Page. <https://www.acog.org/Patients>. Accessed May 2, 2018.